首页> 外文期刊>Journal of Clinical and Diagnostic Research >The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD
【24h】

The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD

机译:茶碱与福莫特罗加布地奈德合用对COPD的疗效,耐受性和安全性研究

获取原文
获取外文期刊封面目录资料

摘要

Background: Chronic obstructive pulmonary disease (COPD) is a common disease causing significant socioeconomic burden. COPD patients, commonly smokers develop resistance to inhaled steroids attributed to deficiency of histone deacetylase 2 (HDAC2). The study of relationship between systemic inflammation and functional performance demonstrated that increased CRP level is inversely related to six minute walk distance (SMWD) and Forced Expired Volume in one second (FEV1). Theophylline restores HDAC2 activity thereby unlocking steroid resistance and potentiating inhaled corticosteroids (ICS) action culminating in reduced airway inflammation and mortality.Aim: To study the effects of addition of Theophylline to the combination of Formoterol plus Budesonide on various objective and subjective parameters in moderate to severe COPD patients and to assess the safety profile of the combination.Setting and study design: A single blinded, prospective, randomized, placebo controlled study at a tertiary care hospital in Jaipur, India.Materials and Methods: Fifty eight patients diagnosed with moderate to severe COPD were randomized into two groups. Group A patients received Formoterol 24 μ g plus budesonide 800 μ g daily in divided doses along with Theophylline while group B patients received Formoterol 24 μ g plus budesonide 800 μ g daily in divided doses along with placebo tablets. Both groups were followed up on 15 th , 30 th & 60 th day. During every visit all patients were assessed subjectively (symptom scoring) and objectively (spirometry, CRP, SMWT) and adverse effects if any were recorded. The obtained data subject to statistical analysis using?Graph pad Instat3? software.Results: Statistically significant improvement with a decline in total symptom score (p < 0.0001) was found with respect to ?Night symptoms?& ?SOB on rising? in group A. Theophylline group showed significant improvement in SMWD and FEV1. Mean fall in CRP was greater in Group A (not statistically significant). No side effects requiring withdrawal of drug were noted with Theophylline.Conclusion: Addition of Theophylline to Formoterol plus Budesonide reduces dyspnea, improves exercise performance and pulmonary functions in moderate to severe COPD. Further studies are required to explore if reduced dosage would have equal efficacy with better safety and tolerability profile.
机译:背景:慢性阻塞性肺疾病(COPD)是一种常见的疾病,会引起巨大的社会经济负担。 COPD患者(通常为吸烟者)对因组蛋白脱乙酰基酶2(HDAC2)缺乏而引起的吸入类固醇产生抵抗力。对系统性炎症与功能表现之间关系的研究表明,CRP水平升高与六分钟步行距离(SMWD)和一秒钟的强迫呼气量(FEV1)成反比。茶碱可恢复HDAC2活性,从而释放类固醇抗药性并增强吸入性糖皮质激素(ICS)的作用,最终降低气道炎症和死亡率。目的:研究在福莫特罗加布地奈德组合物中加入茶碱对中度至中度各种客观和主观参数的影响重度COPD患者并评估该组合的安全性。设置和研究设计:印度斋浦尔一家三级医院的单盲,前瞻性,随机,安慰剂对照研究。材料与方法:58例诊断为中度至重度的患者。重度COPD被随机分为两组。 A组患者每天服用福莫特罗24微克加布地奈德800克和茶碱分次服用,而B组患者每天接受福莫特罗24微克加布地奈德800克的布丁每天服用和安慰剂片。两组均在第15、30和60天进行了随访。在每次访视期间,对所有患者进行主观评估(症状评分)和客观评估(肺活量测定,CRP,SMWT),并记录不良反应(如有)。使用“ Graph pad Instat3”对获得的数据进行统计分析。结果:就“夜间症状”和“ SOB升高”而言,发现总症状评分下降(p <0.0001),具有统计学上的显着改善。茶碱组显示SMWD和FEV1明显改善。 A组中CRP的平均下降幅度更大(无统计学意义)。结论:在福莫特罗加布地奈德中添加茶碱可减轻呼吸困难,改善中重度COPD患者的呼吸困难,改善运动表现和肺功能。需要进行进一步的研究,以探索减少的剂量是否具有相同的疗效以及更好的安全性和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号